1. Home
  2. CERO vs EVAX Comparison

CERO vs EVAX Comparison

Compare CERO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • EVAX
  • Stock Information
  • Founded
  • CERO 2017
  • EVAX 2008
  • Country
  • CERO United States
  • EVAX Denmark
  • Employees
  • CERO N/A
  • EVAX N/A
  • Industry
  • CERO
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CERO
  • EVAX Health Care
  • Exchange
  • CERO Nasdaq
  • EVAX Nasdaq
  • Market Cap
  • CERO 8.4M
  • EVAX 8.7M
  • IPO Year
  • CERO N/A
  • EVAX 2021
  • Fundamental
  • Price
  • CERO $1.80
  • EVAX $2.61
  • Analyst Decision
  • CERO
  • EVAX Strong Buy
  • Analyst Count
  • CERO 0
  • EVAX 3
  • Target Price
  • CERO N/A
  • EVAX $33.33
  • AVG Volume (30 Days)
  • CERO 742.5K
  • EVAX 6.9M
  • Earning Date
  • CERO 02-24-2025
  • EVAX 03-26-2025
  • Dividend Yield
  • CERO N/A
  • EVAX N/A
  • EPS Growth
  • CERO N/A
  • EVAX N/A
  • EPS
  • CERO N/A
  • EVAX N/A
  • Revenue
  • CERO N/A
  • EVAX $3,295,000.00
  • Revenue This Year
  • CERO N/A
  • EVAX $9,039.73
  • Revenue Next Year
  • CERO N/A
  • EVAX $1.47
  • P/E Ratio
  • CERO N/A
  • EVAX N/A
  • Revenue Growth
  • CERO N/A
  • EVAX N/A
  • 52 Week Low
  • CERO $1.70
  • EVAX $2.22
  • 52 Week High
  • CERO $1,238.00
  • EVAX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • CERO 32.70
  • EVAX 40.78
  • Support Level
  • CERO $1.70
  • EVAX $2.30
  • Resistance Level
  • CERO $2.22
  • EVAX $2.90
  • Average True Range (ATR)
  • CERO 0.31
  • EVAX 0.64
  • MACD
  • CERO 0.26
  • EVAX 0.03
  • Stochastic Oscillator
  • CERO 6.76
  • EVAX 7.29

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Share on Social Networks: